Intas has been granted exclusive license rights to commercialise DMB-3115 worldwide, excluding Japan, Korea and certain countries in Asia
Intas Pharmaceuticals has entered into an exclusive license agreement with Meiji and Dong-A Socio Holdings (a parent company of Dong-A ST) to commercialise DMB-3115, a proposed biosimilar to ustekinumab, a recombinant monoclonal antibody for the treatment of autoimmune and inflammatory diseases such as plaque psoriasis, Crohn’s disease and ulcerative colitis.
Under the terms of the agreement, Intas has been granted exclusive license rights to commercialise DMB-3115 worldwide, excluding Japan, Korea and certain countries in Asia. Meiji and Dong-A ST will develop and manufacture DMB-3115 and supply the product to Intas and its worldwide affiliates.
“We are truly excited by this partnership, which brings together the development expertise of Meiji and Dong-A ST with the extensive commercial reach of Intas,” said Vice Chairman, Binish Chudgar. “This agreement underlines our vision and commitment to increasing access to life-changing medicines that can make a real difference to patient lives across the world,” said Chrys Kokino, President of Accord BioPharma, the US speciality subsidiary of Intas.
